This strategy aims to reduce the pro-inflammatory signals that contribute to chronic inflammation in IBD, and is supported by preclinical data demonstrating that therapeutic blockade of LIGHT with neutralizing monoclonal antibodies ameliorates experimental colitis in acute DSS models (29, 31). Here, TNFSF14 is linked to colitis.